The Best Buy in Health: Counting the Lives Behind a 60-Million-Death Decline

Few interventions in global health carry numbers like these. Surveillance estimates cited in the dossier credit measles vaccination with averting roughly 60.3 million deaths between 2000 and 2023, as estimated annual measles deaths fell from about 800,000 to 107,000 — an 87% decline — while global first-dose coverage rose from 71% to 83%. Over the same era, Gavi reports immunizing more than 1.2 billion children and helping halve child mortality across 78 lower-income countries, describing immunization as a 'best buy' with a return on the order of $54 per dollar invested. This is a Factrail analysis of what built those gains — and what could erode them.

Why it matters

The headline welfare measure here is the global under-five mortality rate, which integrates nutrition, immunization, maternal care and sanitation into a single survival number. It fell from 93.6 deaths per 1,000 live births in 1990 to 36.7 in 2023 — less than half its 2000 level. That is durable, verified progress. But the SDG normal line is 25 per 1,000 by 2030, so the indicator remains in deviation: the job is not finished.

How investment moves the indicators

Factrail's causal graph models public and donor investment in immunization systems as a strengthening force on two indicators. First, it raises measles MCV1 coverage (high confidence, roughly a one-year lag): the 71%-to-83% rise coincides with the Gavi era. Second, it lowers under-five mortality (high confidence, roughly a two-year lag), because fewer vaccine-preventable deaths feed directly into the survival measure. The Gavi fact initiates this investment driver; the 2019 Universal Health Care Act, which automatically enrolled every Filipino in the national insurance program, strengthens it — though its direct immunization effect depends on implementation and is rated medium confidence.

What is verified versus uncertain

The deaths-averted and child-mortality figures are high-confidence, drawn from CDC/WHO and UN IGME-based estimates. The investment-intensity series itself is an analytical estimate — a directional reading of financing strength, marked medium confidence — not a measured budget figure. Several mortality data points between the verified 1990, 2000, 2023 and 2024 anchors are interpolated along the documented decline and should be read accordingly.

What changed relative to the normal line

The worry is momentum. MCV1 coverage has plateaued at 83-84%, roughly twelve points below the ~95% herd-immunity normal line, and the dossier notes 14.5 million zero-dose children in 2023. Under-five mortality even ticked up slightly to 37.4 in 2024 from 36.7 in 2023. After the COVID-era dip, the immunization-investment estimate only partially recovered (to about 0.75 from a 0.8 pre-pandemic peak). Stalled coverage plus elevated vaccine hesitancy is the combination the model treats as putting future gains at risk.

Alternative explanations

Progress is multi-causal: rising incomes, better nutrition, oral rehydration, malaria control and improved maternal care all contributed to falling child mortality, so immunization investment is one strong driver among several, not the sole cause. Attribution of the full 60-million figure to any single actor would overreach; the dossier hedges by crediting Gavi, the WHO and national programs jointly.

What may come next

If coverage stays on its plateau and hesitancy holds, the model expects the under-five mortality decline to slow rather than continue at its historical pace — the basis of Factrail's accompanying baseline forecast. The lives behind the 60-million figure are real and already saved; the question is whether the next decade adds to that total or merely defends it.

Sources

The analysis draws on CDC MMWR measles-elimination reporting, WHO child-mortality and routine-vaccination data, UN IGME-based mortality estimates, and Gavi's own reporting — all carried in the dossier, with self-reported organisational figures treated as medium credibility.